

Zeitschriftenartikel (peer reviewed)

1. Buechler R, Wotruba D, Michels L, Theodoridou A, Metzler S, Walitza S, Hänggi J, Kollias S, Rössler W, **Heekeren K** (2020). Cortical Volume Differences in Subjects at Risk for Psychosis Are Driven by Surface Area. *Schizophrenia Bulletin* [Online ahead of print].
2. **Heekeren K**, Antoniadis S, Habermeyer B, Obermann C, Kirschner M, Seifritz E, Rössler W, Kawohl W (2020). Psychiatric Acute Day Hospital as an Alternative to Inpatient Treatment. *Frontiers in Psychiatry* 11:471.
3. Aleksandrowicz A, Hagenmuller F, Haker H, **Heekeren K**, Theodoridou A, Walitza S, Ehli AC, Fallgatter A, Rössler W, Kawohl W (2020). Frontal Brain Activity in Individuals at Risk for Schizophrenic Psychosis and Bipolar Disorder During the Emotional Stroop Task - An fNIRS Study. *Neuroimage: Clinical* [Online ahead of print].
4. Régio Brambilla C, Veselinović T, Rajkumar R, Mauler J, Orth L, Ruch A, Ramkiran S, **Heekeren K**, Kawohl W, Wyss C, Kops ER, Scheins J, Tellmann L, Boers F, Neumaier B, Ermert J, Herzog H, Langen KJ, Jon Shah N, Lerche C, Neuner I (2020). mGluR5 Receptor Availability Is Associated With Lower Levels of Negative Symptoms and Better Cognition in Male Patients With Chronic Schizophrenia. *Human Brain Mapping* [Online ahead of print].
5. Bolton TAW, Wotruba D, Buechler R, Theodoridou A, Michels L, Kollias S, Rössler W, **Heekeren K**, Van De Ville D (2020). Triple Network Model Dynamically Revisited: Lower Salience Network State Switching in Pre-psychosis. *Frontiers in Physiology* 11:66.
6. Jagannath V, Grünblatt E, Theodoridou A, Oneda B, Roth A, Gerstenberg M, Franscini M, Traber-Walker N, Correll CU, **Heekeren K**, Rössler W, Rauch A, Walitza S (2020). Rare copy number variants in individuals at clinical high risk for psychosis: Enrichment of synaptic/brain-related functional pathways. *Am J Med Genet B Neuropsychiatr Genet* 183(2):140-151.
7. Paust T, Theodoridou A, Müller M, Wyss C, Obermann C, Rössler W, **Heekeren K** (2019). Borderline Personality Pathology in an At Risk Mental State Sample. *Frontiers in Psychiatry* 10:838.
8. Hagenmuller F, **Heekeren K**, Roser P, Haker H, Theodoridou A, Walitza S, Rössler W, Kawohl W (2019). Early Somatosensory Processing Over Time in Individuals at Risk to Develop Psychosis. *Frontiers in Psychiatry* 10:47.
9. Schnell T, **Heekeren K**, Daumann J, Gouzoulis-Mayfrank E (2019). Inhibition of return (IOR) in patients with schizophrenia and cannabis use. *Prog Neuropsychopharmacol Biol Psychiatry* 89:65-72.
10. Theodoridou A, Hengartner MP, **Heekeren K**, Dvorsky D, Schultze-Lutter F, Gerstenberg M, Walitza S, Rössler W (2019). Influence of demographic characteristics on attenuated positive psychotic symptoms in a young, help-seeking, at-risk population. *Early Intervention in Psychiatry* 13:53-56.
11. Neuner I, Rajkumar R, Régio Brambilla C, Ramkiran S, Ruch A, Orth L, Farrher E, Mauler J, Wyss C, Rota Kops E, Scheins J, Tellmann L, Lang M, Ermert J, Dammers J, Neumaier B, Lerche C, **Heekeren K**, Kawohl W, Langen K-J, Herzog H, Shah NJ (2019). Simultaneous PET-MR-EEG: Technology, Challenges and Application in Clinical Neuroscience. *IEEE Trans Radiat Plasma Med* 3:377-385.
12. Jagannatha V, Gerstenberg M, Walitza S, Franscini M, **Heekeren K**, Rössler W, Theodoridou A, Grünblatt E (2018). Neuregulin 1 (NRG1) gene expression predicts functional outcomes in individuals at clinical high-risk for psychosis. *Psychiatry Research* 266:143-146.

13. Del Guerra A, Ahmad S, Avram M, Belcari N, Berneking A, Biagi L, Bisogni MG, Brandl F, Cabello J, Camarlinghi N, Cerello P, Choi CH, Coli S, Colpo S, Fleury J, Gagliardi V, Giraudo G, **Heekeren K**, Kawohl W, Kostou T, Lefaucheur JL, Lerche C, Loudos G, Morrocchi M, Muller J, Mustafa M, Neuner I, Papadimitroulas P, Pennazio F, Rajkumar R, Brambilla CR, Rivoire J, Kops ER, Scheins J, Schimpf R, Shah NJ, Sorg C, Sportelli G, Tosetti M, Trincherio R, Wyss C, Ziegler S; TRIMAGE Consortium (2018). TRIMAGE: A dedicated trimodality (PET/MR/EEG) imaging tool for schizophrenia. *European Psychiatry* 50:7-20.
14. Jagannath V, Theodoridou A, Gerstenberg M, Franscini M, **Heekeren K**, Correll CU, Rössler W, Grünblatt E, Walitza S (2017). Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits. *Frontiers in Psychiatry* 8:292.
15. Hengartner MP, **Heekeren K**, Dvorsky D, Walitza S, Rössler W, Theodoridou A (2017). Checking the predictive accuracy of basic symptoms against ultra high-risk criteria and testing of a multivariable prediction model: Evidence from a prospective three-year observational study of persons at clinical high-risk for psychosis. *European Psychiatry* 45:27-35.
16. Hengartner MP, **Heekeren K**, Dvorsky D, Walitza S, Rössler W, Theodoridou A (2017). Course of psychotic symptoms, depression and global functioning in persons at clinical high risk of psychosis: Results of a longitudinal observation study over three years focusing on both converters and non-converters. *Schizophrenia Research* 189:19-26.
17. Harrisberger F, Buechler R, Smieskova R, Lenz C, Walter A, Egloff L, Bendfeldt K, Simon AE, Wotruba D, Theodoridou A, Rössler W, Riecher-Rössler A, Lang UE, **Heekeren K**, Borgwardt S (2016). Alterations in the hippocampus and thalamus in individuals at high risk for psychosis. *NPJ Schizophrenia* 2:16033.
18. Metzler S, Dvorsky D, Wyss C, Nordt C, Walitza S, **Heekeren K**, Rössler W, Theodoridou A (2016). Neurocognition in help-seeking individuals at risk for psychosis: Prediction of outcome after 24 months. *Psychiatry Research* 246:188-194.
19. Xu Z, Mayer B, Müller M, **Heekeren K**, Theodoridou A, Dvorsky D, Metzler S, Oexle N, Walitza S, Rössler W, Rüschi N (2016). Stigma and suicidal ideation among young people at risk of psychosis after one year. *Psychiatry Research* 243:219-224.
20. Ajdacic-Gross V, Rodgers S, Müller M, Hengartner MP, Aleksandrowicz A, Kawohl W, **Heekeren K**, Rössler W, Angst J, Castelao E, Vandeleur C, Preisig M (2016). Pure animal phobia is more specific than other specific phobias. Epidemiological evidence from the Zurich Study, ZInEP and PsyCoLaus. *European Archives of Psychiatry and Clinical Neuroscience* 266(6):567-77.
21. Döring C, Müller M, Hagenmuller F, Ajdacic-Gross V, Haker H, Kawohl W, Rössler W, **Heekeren K** (2016). Mismatch negativity: alterations in adults from the general population who report subclinical psychotic symptoms. *European Psychiatry* 34:9-16.
22. Xu Z, Müller M, **Heekeren K**, Theodoridou A, Metzler S, Dvorsky D, Oexle N, Walitza S, Rössler W, Rüschi N (2016). Pathways between stigma and suicidal ideation among people at risk of psychosis. *Schizophrenia Research* 172(1-3):184-188.
23. Gerstenberg M, Theodoridou A, Traber-Walker N, Franscini M, Wotruba D, Metzler S, Müller M, Dvorsky D, Correll CU, Walitza S, Rössler W, **Heekeren K** (2016). Adolescents and adults at clinical high-risk for psychosis: age-related differences in attenuated positive symptoms syndrome prevalence and entanglement with basic symptoms. *Psychological Medicine* 46(5):1069-1078.
24. Hagenmuller F, **Heekeren K**, Meier M, Theodoridou A, Walitza S, Haker H, Rössler W, Kawohl W (2016). The Loudness Dependence of Auditory Evoked Potentials (LDAEP) in individuals at risk for developing bipolar disorders and schizophrenia. *Clinical Neurophysiology* 127(2):1342-1350.

25. Xu Z, Müller M, **Heekeren K**, Theodoridou A, Dvorsky D, Metzler S, Brabban A, Corrigan PW, Walitza S, Rössler W, Rüscher N (2016). Self-labelling and stigma as predictors of attitudes towards help-seeking among people at risk of psychosis: one year follow-up. *European Archives of Psychiatry and Clinical Neuroscience* 266(1):79-82.
26. Rüscher N, **Heekeren K**, Theodoridou A, Müller M, Corrigan PW, Mayer B, Metzler S, Dvorsky D, Walitza S, Rössler W (2015). Stigma as a stressor and transition to schizophrenia after one year among young people at risk of psychosis. *Schizophrenia Research* 166(1-3):43-48.
27. Metzler S, Dvorsky D, Wyss C, Müller M, Gerstenberg M, Traber-Walker N, Walitza S, Theodoridou A, Rössler W, **Heekeren K** (2015). Changes in neurocognitive functioning during transition to manifest disease: Comparison of individuals at risk for schizophrenic and bipolar affective psychoses. *Psychological Medicine* 45(10): 2123-2134.
28. Wotruba D, **Heekeren K**, Michels L, Buechler R, Simon JJ, Theodoridou A, Kollias S, Rössler W, Kaiser S (2014). Symptom dimensions are associated with reward processing in unmedicated persons at risk for psychosis. *Frontiers in Behavioral Neuroscience* 8:382.
29. Theodoridou A, **Heekeren K**, Dvorsky D, Metzler S, Francini M, Haker H, Kawohl W, Rüscher N, Walitza S and Rössler W (2014). Early recognition of high risk of bipolar disorder and psychosis: an overview of the ZInEP “early recognition” study. *Frontiers in Public Health* 2:166.
30. Hagenmüller F, **Heekeren K**, Theodoridou A, Walitza S, Haker H, Rössler W and Kawohl W (2014). Early somatosensory processing in individuals at risk for developing psychoses. *Frontiers in Behavioral Neuroscience* 8:308.
31. Rüscher N, Müller M, **Heekeren K**, Theodoridou A, Metzler S, Dvorsky D, Corrigan PW, Walitza S, Rössler W (2014). Longitudinal course of self-labeling, stigma stress and well-being among young people at risk of psychosis. *Schizophrenia Research* 158(1-3):82-84.
32. Metzler S, Dvorsky D, Wyss C, Müller M, Traber-Walker N, Walitza S, Theodoridou A, Rössler W, **Heekeren K** (2014). Neurocognitive profiles in help-seeking individuals: comparison of risk for psychosis and bipolar disorder criteria. *Psychological Medicine* 44(16):3543-55.
33. Metzler S, Theodoridou A, Aleksandrowicz A, Müller M, Obermann C, Kawohl W, **Heekeren K** (2014). Evaluation of trait adjectives and ego pathology in schizophrenia: an N400 study. *Psychiatry Research* 215(3):533-539.
34. Rüscher N, Corrigan PW, **Heekeren K**, Theodoridou A, Dvorsky D, Metzler S, Müller M, Walitza S, Rössler W (2014). Well-Being among persons at risk of psychosis: The role of self-labeling, shame, and stigma stress. *Psychiatric Services* 53(4): 483-9.
35. Wotruba D, Michels L, Buechler R, Metzler S, Theodoridou A, Gerstenberg M, Walitza S, Kollias S, Rössler W, **Heekeren K** (2014). Aberrant coupling within and across the default mode, task-positive, and salience network in subjects at risk for psychosis. *Schizophrenia Bulletin* 40(5):1095-1104.
36. Rüscher N, **Heekeren K**, Theodoridou A, Dvorsky D, Müller M, Paust T, Corrigan PW, Walitza S, Rössler W (2013). Attitudes towards help-seeking and stigma among young people at risk for psychosis. *Psychiatry Research* 210(3): 1313-1315.
37. Kohl S, **Heekeren K**, Klosterkötter J, Kuhn J (2013). Prepulse inhibition in psychiatric disorders - Apart from schizophrenia. *Journal of Psychiatric Research* 47(4): 445-452.
38. Hitz K, **Heekeren K**, Obermann C, Huber T, Juckel G, Kawohl W (2012). Examination of the effect of acute levodopa administration on the loudness dependence of auditory evoked potentials (LDAEP) in humans. *Psychopharmacology* 221: 389-396.
39. **Heekeren K** (2011). Führt Cannabiskonsum zu Schizophrenie? *Praxis* 100(22): 1361-1367.

40. Kaiser S, **Heekeren K**, Simon JJ (2011). The negative symptoms of schizophrenia – category or continuum? *Psychopathology* 44(6): 345-353.
41. Mutschler J, Grosshans M, Herwig U, **Heekeren K**, Kawohl W, Brühl A (2011). Pregabalin-induced suicidal ideations. *Pharmacopsychiatry* 44(3): 119.
42. Daumann J, Wagner D, **Heekeren K**, Neukirch A, Thiel CM, Gouzoulis-Mayfrank E (2010). Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. *Journal of Psychopharmacology* 24(10): 1515-1524.
43. Schnell K, **Heekeren K**, Daumann J, Schnell T, Schnitker R, Möller-Hartmann W, Gouzoulis-Mayfrank E (2008). Correlation of passivity symptoms and dysfunctional visuomotor action monitoring in psychosis. *Brain* 131(10): 2783-2797.
44. Daumann J, **Heekeren K**, Neukirch A, Thiel CM, Möller-Hartmann W, Gouzoulis-Mayfrank E (2008). Pharmacological Modulation of the Neural Basis Underlying Inhibition of Return (IOR) in the Human 5-HT_{2A} Agonist and NMDA Antagonist Model of Psychosis. *Psychopharmacology* 200: 573-583.
45. **Heekeren K**, Daumann J, Neukirch A, Kawohl W, Norra C, Waberski TD, Gouzoulis-Mayfrank E (2008). Mismatch negativity generation in the human 5HT_{2A} agonist and NMDA antagonist model of psychosis. *Psychopharmacology* 199: 77-88.
46. Gouzoulis-Mayfrank E, Balke M, Hajsamou S, Ruhrmann S, Schultze-Luther F, Daumann J, **Heekeren K** (2007). Orienting of attention in unmedicated patients with schizophrenia, prodromal subjects and healthy relatives. *Schizophrenia Research* 97(1-3): 35-42.
47. **Heekeren K**, Neukirch A, Daumann J, Stoll M, Obradovic M, Kovar K-A, Geyer MA, Gouzoulis-Mayfrank E (2007). Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. *Journal of Psychopharmacology* 21(3): 312-320.
48. Schnell K, **Heekeren K**, Schnitker R, Daumann J, Weber J, Hesselmann V, Möller-Hartmann W, Thron A, Gouzoulis-Mayfrank E (2007). An fMRI approach to particularize the frontoparietal network for visuomotor action monitoring: Detection of incongruence between test subjects' actions and resulting perceptions. *Neuroimage* 34(1): 332-341.
49. Gouzoulis-Mayfrank E, Arnold S, **Heekeren K** (2006). Deficient inhibition of return in schizophrenia – Further evidence from an independent sample. *Prog Neuropsychopharmacol Biol Psychiatry* 30(1): 42-49.
50. Gouzoulis-Mayfrank E, **Heekeren K**, Neukirch A, Stoll M, Stock C, Daumann J, Obradovic M, Kovar KA (2006). Inhibition of Return (IOR) in the human 5HT_{2A} agonist and NMDA antagonist model of psychosis. *Neuropsychopharmacology* 31(2): 431-441.
51. Gouzoulis-Mayfrank E, **Heekeren K**, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA (2005). Psychological effects of S-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. *Pharmacopsychiatry* 38(6): 301-311.
52. Daumann J, Fischermann T, **Heekeren K**, Henke K, Thron A, Gouzoulis-Mayfrank E (2005). Memory-related hippocampal dysfunction in poly-drug ecstasy (MDMA) users. *Psychopharmacology* 180(4): 607-611.
53. Daumann J, Fischermann T, **Heekeren K**, Thron A, Gouzoulis-Mayfrank E (2004). Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18 months longitudinal functional magnetic resonance imaging (fMRI) study. *Biological Psychiatry* 56: 349-355.

54. Habermeyer E, **Heekeren K** (2004). Anmerkungen zum unkritischen Umgang mit der Diagnose „Kleptomanie“. *Psychiatrische Praxis* 31(1): 40-42.
55. **Heekeren K**, Daumann J, Geyer MA, Gouzoulis-Mayfrank E (2004). Plasticity of the acoustic startle reflex in currently abstinent ecstasy (MDMA) users. *Psychopharmacology* 173: 418-424.
56. **Heekeren K**, Meincke U, Geyer MA, Gouzoulis-Mayfrank E (2004). Attentional modulation of prepulse inhibition (PPI): a new startle paradigm. *Neuropsychobiology* 49: 88-93.
57. Gouzoulis-Mayfrank E, **Heekeren K**, Voss T, Moerth D, Thelen B, Meincke U (2004). Blunted inhibition of return in schizophrenia-evidence from a longitudinal study. *Progr NeuroPsychopharm Biol Psychiatry* 28: 389-396.
58. Gouzoulis-Mayfrank E, Thelen B, Maier S, **Heekeren K**, Kovar KA, Sass H, Spitzer M (2002). Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. *Neuropsychobiology* 45(4): 205-212.
59. Gouzoulis-Mayfrank E, **Heekeren K**, Thelen B, Lindenblatt H, Kovar KA, Sass H, Geyer MA (1998). Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. *Behavioural Pharmacology* 9: 561-566.

Beiträge in Handbüchern

60. **Heekeren K**, Theodoridou A, Rössler W (2016). Früherkennung psychotischer und bipolarer Störungen: erste Ergebnisse und ihre Bedeutung für die klinische Praxis. In: Rössler W (Hg.): Handlungsfelder der psychiatrischen Versorgung. Analysen, Konzepte, Erfahrungen aus dem Zürcher Impulsprogramm zur nachhaltigen Entwicklung der Psychiatrie (ZInEP). Stuttgart: Kohlhammer, 37-48.
61. **Heekeren K** (2013). Tageskliniken. In: Rössler W, Kawohl W (Hg.): Soziale Psychiatrie. Das Handbuch für die psychosoziale Praxis. Band 2. Stuttgart: Kohlhammer, 67-76.
62. Theodoridou A, **Heekeren K** (2013). Indizierte Prävention unter besonderer Berücksichtigung der Früherkennung von Psychosen. In: Rössler W, Kawohl W (Hg.): Soziale Psychiatrie. Das Handbuch für die psychosoziale Praxis. Band 2. Stuttgart: Kohlhammer, 42-52.
63. **Heekeren K**, Kowalewski R, Kawohl W (2013). Ausgewählte Aspekte der sozialpsychiatrischen Pharmakotherapie. In: Rössler W, Kawohl W (Hg.): Soziale Psychiatrie. Das Handbuch für die psychosoziale Praxis. Band 2. Stuttgart: Kohlhammer, 277-289.

Sonstige Zeitschriftenartikel

64. Zehnder U, **Heekeren K**, Kaiser S (2015) Früherkennung und Frühbehandlung von Psychosen: Eine möglichst frühe phasenspezifische Intervention ist entscheidend. *InFo Neurologie & Psychiatrie* Vol.13, Nr 4, 18-22.
65. **Heekeren K**, Kaiser S (2013). Früherkennung und -behandlung schizophrener Psychosen: Frühe Weichenstellung ist entscheidend für einen günstigen Verlauf. *InFo Neurologie & Psychiatrie* Vol.11, Nr 4, 26-28.
66. **Heekeren K** (2013). Früherkennung schizophrener und bipolarer Störungen. *neuro aktuell* 8: 19-20.

67. **Heekeren K**, Rössler W (2012). Was ist möglich mit Früherkennung und Frühintervention? *Pro
Mente Sana Aktuell* 4: 10-11.